/ "Lisa")
Free, discreet delivery
No names, no logos, no delivery fee.
The Numan Weight Loss Programme
Numan's Weight Loss Programme combines MHRA-licensed GLP-1 medication with registered dietitian coaching, delivered via our CQC-regulated online service. We offer:
Prescription medication tailored to you
Continuous clinical oversight
One-to-one coaching to build habits that last
Patients who engage with the Numan Weight Loss Programme, including health coaching, lose 35% more weight in the first 3 months than those who do not.2
Am I eligible for weight loss medication?
National treatment guidelines recommend prescription weight loss medication for adults with a BMI of 30 or above, or a BMI of 27 or above if you also have a weight-related health condition, such as type 2 diabetes, high blood pressure, PCOS, or obstructive sleep apnoea.3,4
You must also be 18 or over and based at a UK delivery address.
However, prescription weight loss medication isn't right for everyone. You won't be eligible if you:3,4
Are pregnant, breastfeeding, or planning a pregnancy
Have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)
Have a history of pancreatitis
Are under 18
Our clinicians will review your full health history before issuing any prescription. If you're not sure whether you qualify, the eligibility check takes two minutes and gives you a clear answer.
Which weight loss medication is right for me?
There are no direct head-to-head trials comparing these medications, and individual responses vary. The right option for you depends on your health history, any existing conditions, and your goals, all of which your clinician will assess during consultation. Here's how the main options compare:*
*The 22.4% figure for Mounjaro comes from the highest dose in the SURMOUNT-1 trial, not every patient reaches that dose, and individual response varies. The same caveat applies to every trial figure in the table.
Our clinicians will recommend the most suitable option during your consultation, based on your health history, current medications, and goals.
| Mounjaro (tirzepatide)⁵ | Wegovy (semaglutide)¹'⁶ | Alli (orlistat)⁷ | |
|---|---|---|---|
| How it works | Dual GLP-1/GIP receptor agonist, reduces appetite and slows gastric emptying | GLP-1 receptor agonist, reduces appetite, slows gastric emptying; observed heart protective properties | Reduces dietary fat absorption in the gut |
| Dosing frequency | Weekly subcutaneous injection | Weekly subcutaneous injection | With each meal (up to 3×/day) |
| Clinical trial efficacy | 22.4% average body weight loss at 72 weeks on highest maintenance dose (SURMOUNT-1)* | 20.7% average body weight loss at 72 weeks on 7.2mg dose (STEP UP, phase 3b) | Approximately 8.5% additional loss vs diet alone in 12-month trials |
| MHRA approval | Weight management; approved November 2023 | Weight management; approved for UK use | Weight management; available OTC (Alli) |
| Starting price | From £209/month (2.5mg starter) | From £129/month (0.25mg starter) | £129/month |
Ongoing clinical support
Access expert clinicians and medical advice.
Pause or cancel any time
You're always in control of your treatment.
Innovative treatments
Advanced, clinically-proven medications.
Rated excellent on Trustpilot
4.5* from over 30,000 people like you.
Trusted
Regulated by the Care Quality Commission.
UK licensed
Medications and clinicians.
WEIGHT LOSS TREATMENTS
How much does the Numan Weight Loss Programme cost?
Prices start at £129 per month for a starter dose of Wegovy (semaglutide 0.25mg) or £209 for Mounjaro (tirzepatide 2.5mg). That covers your medication, unlimited health coaching, clinical monitoring and prescription reviews, and full access to the Numan app.
As your dose increases, the monthly cost adjusts. Maintenance doses will vary depending on the medication and strength. See the full pricing breakdown for every dose tier.
How does the Numan Weight Loss Programme work?
Here’s what to expect from our three-part programme.
STEP 1
Complete your free online consultation
This should take about five minutes. The detailed medical questionnaire is reviewed by a UK-registered prescriber within 24 hours. You’ll get an answer from a qualified clinician within a working day.
STEP 2
Receive your medication and start coaching
Your medication arrives within 2–3 working days in plain, discreet packaging. At the same time, you're introduced to your personal health coach via the Numan app, who'll work with you on a plan tailored to your lifestyle and goals.
STEP 3
Ongoing support throughout your programme
Your clinician reviews your progress, adjusts your dose as needed, and helps manage side effects. Your coach checks in regularly, and you have somewhere to go whenever you need support.
What's included in the programme?
Prescription medication
Ongoing clinical support
One-to-one health coaching
Clinical monitoring
The Numan app
Safety
Is weight loss medication safe?
All medications prescribed through Numan, including Mounjaro and Wegovy, hold full MHRA marketing authorisation for weight management in the UK. Every prescription is issued by a GMC-registered clinician after a proper review of your health history.
Common side effects
The most common are gastrointestinal: nausea, diarrhoea, constipation. Reported by approximately 12–18% of patients.8,9 These are usually temporary and at their worst during dose increases. If they don't, your clinician can slow the titration down to ease them.
If you experience any of these, let your Numan clinician know and they'll be able to help. For a complete list, see the Summary of Product Characteristics at medicines.org.uk. For a complete list, see the Summary of Product Characteristics at medicines.org.uk.
What happens if something goes wrong?
Contact your Numan clinician directly through the app for any questions or concerns. For a serious adverse reaction, contact your GP or call 999.
Adverse reactions can also be reported to the MHRA via the Yellow Card scheme.
More success stories
Over 500,000 people have trusted us to improve their health
The medication alone isn’t enough - it won’t talk you through difficult times or guide you through cravings and diet fatigue. The Numan coach provides that essential support.
/ "ellen")
I know I’m making healthy choices, but there’s no ‘I mustn’t do that or this’. I’m making positive choices for a positive reason.
I didn’t want people to think I wasn’t putting in the effort. But in the end, if something is helping you - improving your health, boosting your confidence - why not do it?
/ "ol")
Numan Research
Obesity is a disease, not a choice
In our State of Obesity report, we found that 57% of Britons still view obesity as a matter of personal choice despite scientific consensus to the contrary. Obesity is a complex, chronic disease shaped by genetics, hormones, gut microbiome, mental health, socio-economic environment, and over 100 interacting factors identified by the Foresight Obesity System Map.10 Willpower is one minor input in a system of extraordinary complexity.
When obesity is understood as a disease, it becomes appropriate to treat it with proven medical interventions, just as we treat hypertension or type 2 diabetes. Numan's approach is grounded in this evidence.
YOUR WEIGHT LOSS JOURNEY
The progress you can expect
TODAY
Simple assessment
Take our online consultation. If eligible, you'll receive your clinically-prescribed medication swiftly. Access your clinicians and coaches through the app.
1-6 MONTHS
Healthy weight loss
Lose weight and learn how to reframe your relationship with food. Expect increased fitness, energy, and confidence.
6-12 MONTHS
Lasting change
With continued support from your coach, adopt healthier lifestyle habits to help maintain weight loss.
UK DOCTORS AND CLINICIANS
Your expert team
Specialists in medicine, nutrition, performance, and diagnostics.
Danielle Brightman
Clinical Director
MPharm PgDip PCert
Zoe Griffiths
VP of Behavioural Medicine
BSc (Hons) RD SCOPE
Shivani Sharma-Savani
Obesity Clinical Lead
MPharm PGCert PCert IP
Faye Townsend
Coaching Operational Lead
AfN BSc BDA SENr (Registered Nutritionist)
Jess Uffindell
Registered Nutritionist
BANT CNHC BSc (Hons)
Victoria Rogers
Head of AI Coaching and Behavioural Science
MSc BSc
Dr Aisha Jinnah
Numan Doctor
BSc MBBS MRCGP
Dr Michael Lacey
Numan Doctor
MBChB BSc (Hons) MRCGP
Dr Alexandra Davidson
Numan Doctor
BSc (Hons) MBBS MRCGP AFHEA MA (Hons) AFMCP
Dr Dimitris Schizas
Numan Doctor
MBBS MRCGP MSC BSSM
FAQs
Your questions answered
KNOWLEDGE
Weight loss: what you need to know
References
Wharton S, Freitas P, Hjelmesæth J, Kabisch M, Kandler K, Lingvay I, et al. Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949–63.
Griffiths, et al. (2025). Impact of Engagement on Weight Loss Outcomes with Tirzepatide and a Digital Health Programme. Conference abstract.
Tirzepatide for managing overweight and obesity. NICE. [accessed 31 Mar 2026] Available from: https://www.nice.org.uk/guidance/ta1026
Semaglutide for managing overweight and obesity. NICE. [accessed 31 Mar 2026] Available from: https://www.nice.org.uk/guidance/ta875
Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–16.
Ryan DH, Lingvay I, Deanfield J, Kahn SE, Barros E, Burguera B, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med. 2024;30(7):2049–57.
Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord. 2000;24(3):306–13.
Mounjaro KwikPen 10mg solution for injection in pre-filled pen. Org.uk. [accessed 31 Mar 2026] Available from: https://www.medicines.org.uk/emc/product/15484/smpc
Wegovy 0.25 mg, FlexTouch solution for injection in pre-filled pen. Org.uk. [accessed 31 Mar 2026] Available from: https://www.medicines.org.uk/emc/product/13799/smpc
Upadhyay J, Farr O, Perakakis N, Ghaly W, Mantzoros C. Obesity as a disease. Med Clin North Am. 2018;102(1):13–33
Wadden TA, Chao AM, Moore M, Tronieri JS, Gilden A, Amaro A, et al. The role of lifestyle modification with second-generation anti-obesity medications: Comparisons, questions, and clinical opportunities. Curr Obes Rep. 2023;12(4):453–73.
Medically reviewed by Hassan Thwaini
Clinical Pharmacist and Copywriter, Master of Pharmacy (MPharm)
Start your treatment journey
Answer a few simple questions to get the treatment you need.
Medically reviewed:
